A drug discovery case history of ‘delta-9-tetrahydrocannabinol, cannabidiol’

Bibliography

• Booth M. Cannabis: a History: Paw Prints; 2008
   Google Scholar
• Di Marzo V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends in Pharmacol Sci 2006;27:134-40
   PubMed Web of Science ®Google Scholar
• Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986;38:151-78
   PubMed Web of Science ®Google Scholar
• Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008;20(Suppl 1):10-14
   PubMed Web of Science ®Google Scholar
• Howlett AC, Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 2000;108:53-70
   PubMed Web of Science ®Google Scholar
• Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003;17:179-202
   PubMed Web of Science ®Google Scholar
• Cabral GA, Raborn ES, Griffin L, CB2 receptors in the brain: role in central immune function. Br J Pharmacol 2008;153:240-51
   PubMed Web of Science ®Google Scholar
• Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: an overview. Immunobiology 2010;215:588-97
   PubMed Web of Science ®Google Scholar
• Oz M. Receptor-independent effects of endocannabinoids on ion channels. Curr Pharm Des 2006;12:227-39
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjogren S, The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092-101
   PubMed Web of Science ®Google Scholar
• Piomelli D, Beltramo M, Giuffrida A, Endogenous cannabinoid signaling. Neurobiol Dis 1998;5:462-73
   PubMed Web of Science ®Google Scholar
• Baker D, Pryce G, Croxford JL, Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001;15:300-2
   PubMed Web of Science ®Google Scholar
• Kubajewska I, Constantinescu CS. Cannabinoids and experimental models of multiple sclerosis. Immunobiology 2010;215:647-57
   PubMed Web of Science ®Google Scholar
• Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001;410:588-92
   PubMed Web of Science ®Google Scholar
• Ligresti A, Cascio MG, Pryce G, New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol 2006;147:83-91
   PubMed Web of Science ®Google Scholar
• Jackson SJ, Diemel LT, Pryce G, Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 2005;233:21-5
   PubMed Web of Science ®Google Scholar
• Long JZ, Nomura DK, Vann RE, Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 2009;106:20270-5
   PubMed Web of Science ®Google Scholar
• Gobbi G, Bambico FR, Mangieri R, Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005;102:18620-5
   PubMed Web of Science ®Google Scholar
• Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol 2008;154:369-83
   PubMed Web of Science ®Google Scholar
• Solinas M, Yasar S, Goldberg SR. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res 2007;56:393-405
   PubMed Web of Science ®Google Scholar
• Vigano D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 2005;81:360-8
   PubMed Web of Science ®Google Scholar
• Panagis G, Vlachou S, Nomikos GG. Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties. Curr Drug Abuse Rev 2008;1:350-74
   PubMedGoogle Scholar
• Caille S, Alvarez-Jaimes L, Polis I, Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 2007;27:3695-702
   PubMed Web of Science ®Google Scholar
• Justinova Z, Panlilio LV, Goldberg SR. Drug addiction. Curr Top Behav Neurosci 2009;1:309-46
   PubMedGoogle Scholar
• Wiskerke J, Pattij T, Schoffelmeer AN, The role of CB1 receptors in psychostimulant addiction. Addict Biol 2008;13:225-38
   PubMed Web of Science ®Google Scholar
• Panlilio LV, Justinova Z, Goldberg SR. Animal models of cannabinoid reward. Br J Pharmacol 2010;160:499-510
   PubMed Web of Science ®Google Scholar
• McCallum AL, Limebeer CL, Parker LA. Reducing endocannabinoid metabolism with the fatty acid amide hydrolase inhibitor, URB597, fails to modify reinstatement of morphine-induced conditioned floor preference and naloxone-precipitated morphine withdrawal-induced conditioned floor avoidance. Pharmacol Biochem Behav 2010;96:496-500
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Freeman TP, Schafer GL, Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 2010;35:1879-85
   PubMed Web of Science ®Google Scholar
• Ligresti A, Petrosino S, Di Marzo V. From endocannabinoid profiling to ‘endocannabinoid therapeutics’. Curr Opin Chem Biol 2009;13:321-31
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215
   PubMed Web of Science ®Google Scholar
• de Meijer EP, Bagatta M, Carboni A, The inheritance of chemical phenotype in Cannabis sativa L. Genetics 2003;163:335-46
   PubMed Web of Science ®Google Scholar
• Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234-46
   PubMed Web of Science ®Google Scholar
• Carlini EA, Karniol IG, Renault PF, Effects of marihuana in laboratory animals and in man. Br J Pharmacol 1974;50:299-309
   PubMed Web of Science ®Google Scholar
• Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993;231:313-14
   PubMed Web of Science ®Google Scholar
• Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006;318:304-11
   PubMed Web of Science ®Google Scholar
• Malfait AM, Gallily R, Sumariwalla PF, The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000;97:9561-6
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Peters M, Murillo-Rodriguez E, Cannabidiol–recent advances. Chem Biodivers 2007;4:1678-92
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Neuropharmacology and therapeutic potential of cannabinoids. Addict Biol 2000;5:37-46
   PubMed Web of Science ®Google Scholar
• Bisogno T, Hanus L, De Petrocellis L, Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-52
   PubMed Web of Science ®Google Scholar
• Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008;4:245-59
   PubMedGoogle Scholar
• Martin BR, Compton DR, Thomas BF, Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 1991;40:471-8
   PubMed Web of Science ®Google Scholar
• Fernandes M, Schabarek A, Coper H, Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat. Psychopharmacologia 1974;38:329-38
   PubMed Web of Science ®Google Scholar
• Varvel SA, Wiley JL, Yang R, Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 2006;186:226-34
   PubMed Web of Science ®Google Scholar
• Welburn PJ, Starmer GA, Chesher GB, Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacologia 1976;46:83-5
   PubMed Web of Science ®Google Scholar
• Cluny NL, Naylor RJ, Whittle BA, The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus. Basic Clin Pharmacol Toxicol 2008;103:150-6
   PubMed Web of Science ®Google Scholar
• Balster RL, Prescott WR. Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 1992;16:55-62
   PubMed Web of Science ®Google Scholar
• Vann RE, Gamage TF, Warner JA, Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 2008;94:191-8
   PubMed Web of Science ®Google Scholar
• Malone DT, Jongejan D, Taylor DA. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 2009;93:91-6
   PubMed Web of Science ®Google Scholar
• Long LE, Chesworth R, Huang XF, A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 2010;13:861-76
   PubMed Web of Science ®Google Scholar
• Baker PB, Gough TA, Taylor BJ. The physical and chemical features of Cannabis plants grown in the United Kingdom of Great Britain and Northern Ireland from seeds of known origin–Part II: second generation studies. Bull Narc 1983;35:51-62
   PubMedGoogle Scholar
• House of Lords. Cannabis: the scientific and medical evidence. London: house of Lords Select Committee on Science and Technology, Stationery Office; 1998
   Google Scholar
• British Medical Association. Therapeutic uses of cannabis: Harwood Academic Publishers; 1997
   Google Scholar
• Rog DJ. Cannabis-based medicines in multiple sclerosis – a review of clinical studies. Immunobiology 2010;215:658-72
   PubMed Web of Science ®Google Scholar
• D'souza DC, Perry E, MacDougall L, The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004;29:1558-72
   PubMed Web of Science ®Google Scholar
• Hallak JE, Dursun SM, Bosi DC, The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:198-202
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 1991;104:260-4
   PubMed Web of Science ®Google Scholar
• Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005;512:199-205
   PubMed Web of Science ®Google Scholar
• Guimaraes VM, Zuardi AW, Del Bel EA, Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci 2004;75:633-8
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Allen P, Bhattacharyya S, Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010;13:421-32
   PubMed Web of Science ®Google Scholar
• Soares Vde P, Campos AC, Bortoli VC, Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res 2010;213:225-9
   PubMed Web of Science ®Google Scholar
• Zanelati TV, Biojone C, Moreira FA, Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 2010;159:122-8
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Crippa JA, Hallak JE, Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39:421-9
   PubMed Web of Science ®Google Scholar
• Zuardi A, Crippa J, Dursun S, Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol 2010;24:135-7
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Crippa JA, Bhattacharyya S, Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009;66:95-105
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008;192:306-7
   PubMed Web of Science ®Google Scholar
• Juckel G, Roser P, Nadulski T, Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res 2007;97:109-17
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Morrison PD, Fusar-Poli P, Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010;35:764-74
   PubMed Web of Science ®Google Scholar
• Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105:1-25
   PubMed Web of Science ®Google Scholar
• Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 1998;30:187-96
   PubMed Web of Science ®Google Scholar
• Maykut MO. Health consequences of acute and chronic marihuana use. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:209-38
   PubMed Web of Science ®Google Scholar
• Morgan VA, Leonard H, Bourke J, Intellectual disability co-occurring with schizophrenia and other psychiatric illness: population-based study. Br J Psychiatry 2008;193:364-72
   PubMed Web of Science ®Google Scholar
• Thomas A, Baillie GL, Phillips AM, Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007;150:613-23
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjogren S, The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092-101
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Review for special issue on cannabinoids: ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008;13:147-59
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Schafer G, Freeman TP, Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010;197:285-90
   PubMed Web of Science ®Google Scholar
• Karschner EL, Darwin WD, Goodwin RS, Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 2011;57:66-75
   PubMed Web of Science ®Google Scholar
• Whittle BA, Guy GW, Robson P. prospects for new cannabis-based prescription medicines. J Cannabis Ther 2001;1:133-52
   Google Scholar
• Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers 2007;4:1729-43
   PubMed Web of Science ®Google Scholar
• Guy GW, Flint ME. A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of cannabis based medicine extracts (CBMEs), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT). J Cannabis Ther 2003;3:35-77
   Google Scholar
• Guy GW, Robson PJ. A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). J Cannabis Ther 2003;3:121-52
   Google Scholar
• Guy GW, Robson PJ. A phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther 2003;3:79-120
   Google Scholar
• Smith PF. GW-1000. GW Pharmaceuticals. Curr Opin Investig Drugs 2004;5:748-54
   PubMedGoogle Scholar
• Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 2007;150:519-25
   PubMed Web of Science ®Google Scholar
• Patel ASC, Wright S, Guy G, The evaluation of the effects of Sativex (THC:CBD) on the inhibition of spasticity in an experimental model of multiple sclerosis. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Gotteborg. Mult Scler; 2010;S234: P 680
   Google Scholar
• Wade DT, Makela P, Robson P, Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
   PubMed Web of Science ®Google Scholar
• Collin C, Duncombe P. Meta-analysis of the effects of Sativex on spasticity associated with multiple sclerosis. Mult Scler 2006;12:S13
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6
   PubMed Web of Science ®Google Scholar
• Ambler Z, Davies P, Gasperini C, A two-phase study of Sativex in the relief of spasticity due to multiple sclerosis: phase A single-blind response assessment followed by phase B double-blind, randomised, placebo-controlled, parallel- group study. Mult Scler 2009;S258:15
   Google Scholar
• Centonze D, Mori F, Koch G, Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci 2009;30:531-4
   PubMed Web of Science ®Google Scholar
• Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003;4:CD001332
   PubMedGoogle Scholar
• Zajicek J, Fox P, Sanders H, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Farrar JT, Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
   PubMed Web of Science ®Google Scholar
• Anwar K, Barnes MP. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation 2009;24:333-40
   PubMed Web of Science ®Google Scholar
• Wade DT, Collin C, Stott C, Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010;16:707-14
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela PM, House H, Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45
   PubMed Web of Science ®Google Scholar
• Notcutt W, Davies P, Langford R, Results of a randomised withdrawal study of subjects with spasticity due to multiple sclerosis who were receiving long term Sativex. Mult Scler 2009;S258:15
   Google Scholar
• Conte A, Bettolo CM, Onesti E, Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain 2009;13:472-7
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-19
   PubMed Web of Science ®Google Scholar
• Health CDahp. Aproval with conditions of SATIVEX (Tetranabinex® and Nabidiolex®). Fact sheet. In: Health, editor, Ottawa (ON). Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/sativex_fs_fd_091289-eng.php; 2005
   Google Scholar
• Ratcliffe S, Metz L, Ambler Z. Efficacy results of a study of THC:CBD in central neuropathic pain due to multiple sclerosis. Mult Scler 2008;S158:14
   Google Scholar
• Lienau FS, Fullgraf H, Moser A, Why do cannabinoids not show consistent effects as analgetic drugs in multiple sclerosis? Eur J Neurol 2007;14:1162-9
   PubMed Web of Science ®Google Scholar
• Iskedjian M, Desjardins O, Piwko C, Willingness to pay for a treatment for pain in multiple sclerosis. Pharmacoeconomics 2009;27:149-58
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
   PubMed Web of Science ®Google Scholar
• Brady CM, DasGupta R, Dalton C, An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004;10:425-33
   PubMed Web of Science ®Google Scholar
• Kavia R, De Ridder D, Constantinescu C, Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010;16:1349-59
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007;29:2068-79
   PubMed Web of Science ®Google Scholar
• Constantinescu CS, Sarantis N. Long-term open-label treatment with Sativex in patients with Multiple Sclerosis. Mult Scler 2006;S111:12
   Google Scholar
• Russo EB. Role of cannabis and cannabinoids in pain management. In: Weiner, editor, Pain management: a practical guide for clinicians. CRC Press; 2002
   Google Scholar
• Elmes SJ, Winyard LA, Medhurst SJ, Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 2005;118:327-35
   PubMed Web of Science ®Google Scholar
• Bonica JJ. Evolution and current status of pain programs. J Pain Symptom Manage 1990;5:368-74
   PubMedGoogle Scholar
• Health CDahp. Authorization with conditions of SATIVEX (Tetranabinex® and Nabidiolex®). Fact sheet. In: Canada, editor, Ottawa (ON). Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/sativex_fs_fd_109461-eng.php; 2007
   Google Scholar
• Johnson JR, Burnell-Nugent M, Lossignol D, Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010;39:167-79
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88
   PubMed Web of Science ®Google Scholar
• Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 2006;42:495-503
   PubMed Web of Science ®Google Scholar
• Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006;7:607-15
   PubMed Web of Science ®Google Scholar
• Wade DT, Robson P, House H, A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21-9
   PubMed Web of Science ®Google Scholar
• Notcutt W, Price M, Miller R, Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1′ studies. Anaesthesia 2004;59:440-52
   PubMed Web of Science ®Google Scholar
• Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112:299-306
   PubMed Web of Science ®Google Scholar
• Nurmikko TJ, Serpell MG, Hoggart B, Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133:210-20
   PubMed Web of Science ®Google Scholar
• Blake DR, Robson P, Ho M, Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006;45:50-2
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-81
   PubMed Web of Science ®Google Scholar
• Selvarajah D, Gandhi R, Emery CJ, Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 2010;33:128-30
   PubMed Web of Science ®Google Scholar
• Johnson SC, Saykin AJ, Flashman LA, Brain activation on fMRI and verbal memory ability: functional neuroanatomic correlates of CVLT performance. J Int Neuropsychol Soc 2001;7:55-62
   PubMed Web of Science ®Google Scholar
• Aragona M, Onesti E, Tomassini V, Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol 2009;32:41-7
   PubMed Web of Science ®Google Scholar
• Samaha AN, Robinson TE. Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 2005;26:82-7
   PubMed Web of Science ®Google Scholar
• Moreira FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 2009;23:133-44
   PubMed Web of Science ®Google Scholar
• Yamaori S, Kushihara M, Yamamoto I, Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010;79:1691-8
   PubMed Web of Science ®Google Scholar
• Berrendero F, Sanchez A, Cabranes A, Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 2001;41:195-202
   PubMed Web of Science ®Google Scholar
• Cabranes A, Venderova K, de Lago E, Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 2005;20:207-17
   PubMed Web of Science ®Google Scholar
• Ramil E, Sanchez AJ, Gonzalez-Perez P, The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain. Mult Scler 2010;16:139-46
   PubMed Web of Science ®Google Scholar
• Gilbert GL, Kim HJ, Waataja JJ, Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 2007;1128:61-9
   PubMed Web of Science ®Google Scholar
• Jean-Gilles L, Feng S, Tench CR, Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 2009;287:212-15
   PubMed Web of Science ®Google Scholar